CELL REGULATORY SIALOPROTEIN

CERES(Cell Regulatory SialoProtein，细胞调节唾液酸蛋白)是一种分子。 抑制原代、传代和转化的细胞系，2.影响细胞 从昆虫和人类这样不同的物种，3.使一种细胞系 末端分化，4.可逆性抑制其他品系(90%-98% 细胞恢复)，5.具体地阻止G1/S界面附近的细胞， 6.同步释放细胞进入S期，然后有丝分裂 (同步化至少通过一个额外的细胞周期保持)。 CERES与所有已知的药物和细胞表面成分不同 在功能上并根据有限的肽序列和 初步的DNA序列数据可用。 这项研究的目的是确定使用CERES来 改进和提高细胞培养效率，提供新的模式 用于分化；并测试各种癌细胞系以确定 对谷神星的敏感性或抵抗力。初步数据显示 细胞的差异敏感性提示潜在的治疗用途。 Ceres的独家许可方SynchroCell相信这一点和相关 分子将成为研究界的重要产品， 显著地有助于理解调控和癌症的发生和发展 作为一种具有商业意义的细胞培养工具。改善癌症 疗法是Ceres和所获得的知识的潜在应用 在谷神星的帮助下。

CeReS (Cell Regulatory Sialoprotein) is a molecule demonstrated to: 1. Inhibit primary, continuous and transformed cell lines, 2. Affect cells from species as diverse as insects and humans, 3. Cause one cell line to terminally differentiate, 4. Reversibly inhibit other lines (90%-98% of the cells recover), 5. Specifically arrest cells near the Gl/S interface, 6. Synchronously release cells to enter S phase and then mitosis (synchronization remains through at least one additional cell cycle). CeReS is distinct from all known drugs and cell surface components functionally and according to the limited peptide sequence and preliminary DNA sequence data available. The aims of this study are to determine the feasibility of using CeReS to improve and increase efficiency of cell culture, to provide new models for differentiation; and to test a wide variety of cancer cell lines for sensitivity or resistance to CeReS. Preliminary data indicates differential sensitivity of cells suggesting potential therapeutic uses. SynchroCell, the exclusive licensee of CeReS, believes this and related molecules will be important products for the research community, significantly aiding in understanding regulation and carcinogenesis and as a cell culture tool of commercial importance. Improved cancer therapies are potential applications of CeReS and of the knowledge gained with the aid of CeReS.